Christine M. Eng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Christine M. Eng has a total of 186 co-authors. Here are the top co-authors by number of shared publications:
Yaping Yang
Baylor College of Medicine
4 shared publications- Yaping Yang
Baylor College of Medicine
4 shared publications Arthur L. Beaudet
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas
3 shared publications- Donna Marie Muzny
Human Genome Sequencing Center, Baylor College of Medicine, Houston, USA
3 shared publications - Richard A. Gibbs
Baylor College of Medicine
3 shared publications Alecia Willis
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas
2 shared publications
Latest Publications
- Open Access
DYRK1A -related intellectual disability: a syndrome associated with congenital anomalies of the kidney and urinary tract
Purpose: Haploinsufficiency of DYRK1A causes a recognizable clinical syndrome. The goal of this paper is to investigate congenital anomalies of the kidney and urinary tract (CAKUT) and genital defects (GD) in patients with DYRK1A mutations. Methods: A large database of clinical exome sequencing (ES) was queried for de novo DYRK1A mutations and CAKUT/GD phenotypes were characterized. Xenopus laevis (frog) was chosen as a model organism to assess Dyrk1a’s role in renal development. Results: Phenotypic details and mutations of 19 patients were compiled after an initial observation that one patient with a de novo pathogenic mutation in DYRK1A had GD. CAKUT/GD data were available from 15 patients, 11 of whom present with CAKUT/GD. Studies in Xenopus embryos demonstrate that knockdown of Dyrk1a disrupts the development of segments of developing embryonic nephrons, which ultimately give rise to the entire genitourinary (GU) tract. These defects could be rescued by co-injecting wildtype human DYRK1A RNA, but not with truncated DYRK1A R205 * RNA. Conclusion: Evidence supports routine GU screening of all individuals with de novo DYRK1A pathogenic variants to ensure optimized clinical management. Collectively, the reported clinical data and loss of function studies in Xenopus substantiate a novel role for DYRK1A in GU development.
Open AccessDYRK1A -related intellectual disability: a syndrome associated with congenital anomalies of the kidney and urinary tract
Purpose: Haploinsufficiency of DYRK1A causes a recognizable clinical syndrome. The goal of this paper is to investigate congenital anomalies of the kidney and urinary tract (CAKUT) and genital defects (GD) in patients with DYRK1A mutations. Methods: A large database of clinical exome sequencing (ES) was queried for de novo DYRK1A mutations and CAKUT/GD phenotypes were characterized. Xenopus laevis (frog) was chosen as a model organism to assess Dyrk1a’s role in renal development. Results: Phenotypic details and mutations of 19 patients were compiled after an initial observation that one patient with a de novo pathogenic mutation in DYRK1A had GD. CAKUT/GD data were available from 15 patients, 11 of whom present with CAKUT/GD. Studies in Xenopus embryos demonstrate that knockdown of Dyrk1a disrupts the development of segments of developing embryonic nephrons, which ultimately give rise to the entire genitourinary (GU) tract. These defects could be rescued by co-injecting wildtype human DYRK1A RNA, but not with truncated DYRK1A R205 * RNA. Conclusion: Evidence supports routine GU screening of all individuals with de novo DYRK1A pathogenic variants to ensure optimized clinical management. Collectively, the reported clinical data and loss of function studies in Xenopus substantiate a novel role for DYRK1A in GU development.
- Open Access
- 28 September 2018
- Published by Springer Nature in Genome Medicine
- Vol. 10 (1) , 1-14
Clinical exome sequencing for fetuses with ultrasound abnormalities and a suspected Mendelian disorder
Exome sequencing is now being incorporated into clinical care for pediatric and adult populations, but its integration into prenatal diagnosis has been more limited. One reason for this is the paucity of information about the clinical utility of exome sequencing in the prenatal setting. We retrospectively reviewed indications, results, time to results (turnaround time, TAT), and impact of exome results for 146 consecutive “fetal exomes” performed in a clinical diagnostic laboratory between March 2012 and November 2017. We define a fetal exome as one performed on a sample obtained from a fetus or a product of conception with at least one structural anomaly detected by prenatal imaging or autopsy. Statistical comparisons were performed using Fisher’s exact test. Prenatal exome yielded an overall molecular diagnostic rate of 32% (n = 46/146). Of the 46 molecular diagnoses, 50% were autosomal dominant disorders (n = 23/46), 41% were autosomal recessive disorders (n = 19/46), and 9% were X-linked disorders (n = 4/46). The molecular diagnostic rate was highest for fetuses with anomalies affecting multiple organ systems and for fetuses with craniofacial anomalies. Out of 146 cases, a prenatal trio exome option designed for ongoing pregnancies was performed on 62 fetal specimens, resulting in a diagnostic yield of 35% with an average TAT of 14 days for initial reporting (excluding tissue culture time). The molecular diagnoses led to refined recurrence risk estimates, altered medical management, and informed reproductive planning for families. Exome sequencing is a useful diagnostic tool when fetal structural anomalies suggest a genetic etiology, but other standard prenatal genetic tests did not provide a diagnosis.
- 28 September 2018
- Published by Springer Nature in Genome Medicine
- Vol. 10 (1) , 1-14
Open AccessClinical exome sequencing for fetuses with ultrasound abnormalities and a suspected Mendelian disorder
Exome sequencing is now being incorporated into clinical care for pediatric and adult populations, but its integration into prenatal diagnosis has been more limited. One reason for this is the paucity of information about the clinical utility of exome sequencing in the prenatal setting. We retrospectively reviewed indications, results, time to results (turnaround time, TAT), and impact of exome results for 146 consecutive “fetal exomes” performed in a clinical diagnostic laboratory between March 2012 and November 2017. We define a fetal exome as one performed on a sample obtained from a fetus or a product of conception with at least one structural anomaly detected by prenatal imaging or autopsy. Statistical comparisons were performed using Fisher’s exact test. Prenatal exome yielded an overall molecular diagnostic rate of 32% (n = 46/146). Of the 46 molecular diagnoses, 50% were autosomal dominant disorders (n = 23/46), 41% were autosomal recessive disorders (n = 19/46), and 9% were X-linked disorders (n = 4/46). The molecular diagnostic rate was highest for fetuses with anomalies affecting multiple organ systems and for fetuses with craniofacial anomalies. Out of 146 cases, a prenatal trio exome option designed for ongoing pregnancies was performed on 62 fetal specimens, resulting in a diagnostic yield of 35% with an average TAT of 14 days for initial reporting (excluding tissue culture time). The molecular diagnoses led to refined recurrence risk estimates, altered medical management, and informed reproductive planning for families. Exome sequencing is a useful diagnostic tool when fetal structural anomalies suggest a genetic etiology, but other standard prenatal genetic tests did not provide a diagnosis.
- 22 June 2018
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (suppl_2) , i184
TBIO-20. CLINICAL TUMOR WHOLE EXOME SEQUENCING FOR PEDIATRIC NEURO-ONCOLOGY PATIENTS – RESULTS FROM THE BAYLOR ADVANCING SEQUENCING IN CHILDHOOD CANCER CARE (BASIC3) CLINICAL SEQUENCING STUDY
Tumor mutations detected by genomic tests such as whole-exome sequencing (WES) have the potential to affect clinical management; however, data regarding clinical utility in pediatric neuro-oncology are limited. In order to investigate this topic, enrollment onto the BASIC3 clinical exome sequencing study was offered to children with newly-diagnosed CNS and non-CNS solid tumors. WES was performed on tumor (when available) and blood specimens in a certified clinical laboratory, with resulting genetic variants categorized by perceived clinical relevance and reported to the electronic health record. Mutations were also annotated following recent consensus guidelines (Li et al. J Mol Diagn 2017). WES was performed on 71 tumors obtained from 70 of 98 patients with CNS tumors on the BASIC3 study (71%), including embryonal tumors (medulloblastoma, n=18; PNET or pineoblastoma, n=5), LGG (n=9), HGG (n=7), and ependymal tumors (n=9). Analysis per the new guidelines revealed 21% (15/71) of tumors harbored a variant of “Strong Clinical Significance” (Tier 1) and 27% (19/71) a variant of “Potential Clinical Significance” (Tier 2). Targetable mutations involved the MAPK pathway (BRAF x 6, KRAS, FGFR1), PI3K/MTOR pathway (TSC1, PIK3CA), SWI/SNF family (SMARCB1, SMARCA4), and other protein kinases (PDGFRA x 2). The rate of clinically relevant mutations differed by histology, with frequent variants in LGG (4/9, 44%), HGG (6/7, 86%), and medulloblastoma (7/18, 39%), but not ependymal tumors (0/9, 0%). These data highlight the promise of clinical genomic testing for pediatric brain tumor patients as well as the need for integrated (DNA/RNA) genomic tumor testing to maximize diagnostic yield.
- 22 June 2018
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (suppl_2) , i184
TBIO-20. CLINICAL TUMOR WHOLE EXOME SEQUENCING FOR PEDIATRIC NEURO-ONCOLOGY PATIENTS – RESULTS FROM THE BAYLOR ADVANCING SEQUENCING IN CHILDHOOD CANCER CARE (BASIC3) CLINICAL SEQUENCING STUDY
Tumor mutations detected by genomic tests such as whole-exome sequencing (WES) have the potential to affect clinical management; however, data regarding clinical utility in pediatric neuro-oncology are limited. In order to investigate this topic, enrollment onto the BASIC3 clinical exome sequencing study was offered to children with newly-diagnosed CNS and non-CNS solid tumors. WES was performed on tumor (when available) and blood specimens in a certified clinical laboratory, with resulting genetic variants categorized by perceived clinical relevance and reported to the electronic health record. Mutations were also annotated following recent consensus guidelines (Li et al. J Mol Diagn 2017). WES was performed on 71 tumors obtained from 70 of 98 patients with CNS tumors on the BASIC3 study (71%), including embryonal tumors (medulloblastoma, n=18; PNET or pineoblastoma, n=5), LGG (n=9), HGG (n=7), and ependymal tumors (n=9). Analysis per the new guidelines revealed 21% (15/71) of tumors harbored a variant of “Strong Clinical Significance” (Tier 1) and 27% (19/71) a variant of “Potential Clinical Significance” (Tier 2). Targetable mutations involved the MAPK pathway (BRAF x 6, KRAS, FGFR1), PI3K/MTOR pathway (TSC1, PIK3CA), SWI/SNF family (SMARCB1, SMARCA4), and other protein kinases (PDGFRA x 2). The rate of clinically relevant mutations differed by histology, with frequent variants in LGG (4/9, 44%), HGG (6/7, 86%), and medulloblastoma (7/18, 39%), but not ependymal tumors (0/9, 0%). These data highlight the promise of clinical genomic testing for pediatric brain tumor patients as well as the need for integrated (DNA/RNA) genomic tumor testing to maximize diagnostic yield.
- Open Access
Phenotypic expansion in DDX3X – a common cause of intellectual disability in females
De novo variants in DDX3X account for 1-3% of unexplained intellectual disability (ID), one of the most common causes of ID, in females. Forty-seven patients (44 females, 3 males) have been described. We identified 29 additional individuals carrying 27 unique DDX3X variants in the setting of complex clinical presentations including developmental delay or ID. In addition to previously reported manifestations, rare or novel phenotypes were identified including respiratory problems, congenital heart disease, skeletal muscle mitochondrial DNA depletion, and late-onset neurologic decline. Our findings expand the spectrum of DNA variants and phenotypes associated with DDX3X disorders.
Open AccessPhenotypic expansion in DDX3X – a common cause of intellectual disability in females
De novo variants in DDX3X account for 1-3% of unexplained intellectual disability (ID), one of the most common causes of ID, in females. Forty-seven patients (44 females, 3 males) have been described. We identified 29 additional individuals carrying 27 unique DDX3X variants in the setting of complex clinical presentations including developmental delay or ID. In addition to previously reported manifestations, rare or novel phenotypes were identified including respiratory problems, congenital heart disease, skeletal muscle mitochondrial DNA depletion, and late-onset neurologic decline. Our findings expand the spectrum of DNA variants and phenotypes associated with DDX3X disorders.
- Top Cited PapersOpen Access
- 12 November 2014
- Published by American Medical Association (AMA) in JAMA
- Vol. 312 (18) , 1870-1879
Molecular Findings Among Patients Referred for Clinical Whole-Exome Sequencing
We previously reported a molecular diagnosis rate of 25% for the first 250 patients without prior diagnosis who were referred to our diagnostic laboratory for whole-exome sequencing.1 Quiz Ref ID Whole-exome sequencing analyzes the exons or coding regions of thousands of genes simultaneously using next-generation sequencing techniques. By sequencing the exome of a patient and comparing it with a normal reference sequence, variations in an individual’s DNA sequence can be identified and related back to the individual’s medical concerns in an effort to discover the cause of the medical disorder. The overall molecular diagnostic rate was higher than several other comparable genetic tests, including chromosome studies (5%-10%)2,3 and chromosomal microarray analysis (15%-20%).4 Notably, in 4 separate cases, molecular findings were reported for 2 Mendelian disorders in the same patient, with clinical features characteristic of the 2 different Mendelian disorders. Secondary (incidental) findings were also observed at a low rate.1,5-7
- 12 November 2014
- Published by American Medical Association (AMA) in JAMA
- Vol. 312 (18) , 1870-1879
Top Cited PapersOpen AccessMolecular Findings Among Patients Referred for Clinical Whole-Exome Sequencing
We previously reported a molecular diagnosis rate of 25% for the first 250 patients without prior diagnosis who were referred to our diagnostic laboratory for whole-exome sequencing.1 Quiz Ref ID Whole-exome sequencing analyzes the exons or coding regions of thousands of genes simultaneously using next-generation sequencing techniques. By sequencing the exome of a patient and comparing it with a normal reference sequence, variations in an individual’s DNA sequence can be identified and related back to the individual’s medical concerns in an effort to discover the cause of the medical disorder. The overall molecular diagnostic rate was higher than several other comparable genetic tests, including chromosome studies (5%-10%)2,3 and chromosomal microarray analysis (15%-20%).4 Notably, in 4 separate cases, molecular findings were reported for 2 Mendelian disorders in the same patient, with clinical features characteristic of the 2 different Mendelian disorders. Secondary (incidental) findings were also observed at a low rate.1,5-7
- 1 October 2014
- Published by Oxford University Press (OUP)
- p. 303-327
Enzyme Replacement and Other Therapies for the Lysosomal Storage Disorders
- 1 October 2014
- Published by Oxford University Press (OUP)
- p. 303-327
Enzyme Replacement and Other Therapies for the Lysosomal Storage Disorders
- Top Cited Papers
- 17 October 2013
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 369 (16) , 1502-1511
Clinical Whole-Exome Sequencing for the Diagnosis of Mendelian Disorders
Whole-exome sequencing is a diagnostic approach for the identification of molecular defects in patients with suspected genetic disorders. We developed technical, bioinformatic, interpretive, and validation pipelines for whole-exome sequencing in a certified clinical laboratory to identify sequence variants underlying disease phenotypes in patients. We present data on the first 250 probands for whom referring physicians ordered whole-exome sequencing. Patients presented with a range of phenotypes suggesting potential genetic causes. Approximately 80% were children with neurologic phenotypes. Insurance coverage was similar to that for established genetic tests. We identified 86 mutated alleles that were highly likely to be causative in 62 of the 250 patients, achieving a 25% molecular diagnostic rate (95% confidence interval, 20 to 31). Among the 62 patients, 33 had autosomal dominant disease, 16 had autosomal recessive disease, and 9 had X-linked disease. A total of 4 probands received two nonoverlapping molecular diagnoses, which potentially challenged the clinical diagnosis that had been made on the basis of history and physical examination. A total of 83% of the autosomal dominant mutant alleles and 40% of the X-linked mutant alleles occurred de novo. Recurrent clinical phenotypes occurred in patients with mutations that were highly likely to be causative in the same genes and in different genes responsible for genetically heterogeneous disorders. Whole-exome sequencing identified the underlying genetic defect in 25% of consecutive patients referred for evaluation of a possible genetic condition. (Funded by the National Human Genome Research Institute.)
- 17 October 2013
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 369 (16) , 1502-1511
Top Cited PapersClinical Whole-Exome Sequencing for the Diagnosis of Mendelian Disorders
Whole-exome sequencing is a diagnostic approach for the identification of molecular defects in patients with suspected genetic disorders. We developed technical, bioinformatic, interpretive, and validation pipelines for whole-exome sequencing in a certified clinical laboratory to identify sequence variants underlying disease phenotypes in patients. We present data on the first 250 probands for whom referring physicians ordered whole-exome sequencing. Patients presented with a range of phenotypes suggesting potential genetic causes. Approximately 80% were children with neurologic phenotypes. Insurance coverage was similar to that for established genetic tests. We identified 86 mutated alleles that were highly likely to be causative in 62 of the 250 patients, achieving a 25% molecular diagnostic rate (95% confidence interval, 20 to 31). Among the 62 patients, 33 had autosomal dominant disease, 16 had autosomal recessive disease, and 9 had X-linked disease. A total of 4 probands received two nonoverlapping molecular diagnoses, which potentially challenged the clinical diagnosis that had been made on the basis of history and physical examination. A total of 83% of the autosomal dominant mutant alleles and 40% of the X-linked mutant alleles occurred de novo. Recurrent clinical phenotypes occurred in patients with mutations that were highly likely to be causative in the same genes and in different genes responsible for genetically heterogeneous disorders. Whole-exome sequencing identified the underlying genetic defect in 25% of consecutive patients referred for evaluation of a possible genetic condition. (Funded by the National Human Genome Research Institute.)
- Open Access
- 27 June 2013
- Published by Springer Nature in Genome Medicine
- Vol. 5 (6) , 57
Exome sequencing resolves apparent incidental findings and reveals further complexity of SH3TC2 variant alleles causing Charcot-Marie-Tooth neuropathy
Background: The debate regarding the relative merits of whole genome sequencing (WGS) versus exome sequencing (ES) centers around comparative cost, average depth of coverage for each interrogated base, and their relative efficiency in the identification of medically actionable variants from the myriad of variants identified by each approach. Nevertheless, few genomes have been subjected to both WGS and ES, using multiple next generation sequencing platforms. In addition, no personal genome has been so extensively analyzed using DNA derived from peripheral blood as opposed to DNA from transformed cell lines that may either accumulate mutations during propagation or clonally expand mosaic variants during cell transformation and propagation. Methods: We investigated a genome that was studied previously by SOLiD chemistry using both ES and WGS, and now perform six independent ES assays (Illumina GAII (x2), Illumina HiSeq (x2), Life Technologies' Personal Genome Machine (PGM) and Proton), and one additional WGS (Illumina HiSeq). Results: We compared the variants identified by the different methods and provide insights into the differences among variants identified between ES runs in the same technology platform and among different sequencing technologies. We resolved the true genotypes of medically actionable variants identified in the proband through orthogonal experimental approaches. Furthermore, ES identified an additional SH3TC2 variant (p.M1?) that likely contributes to the phenotype in the proband. Conclusions: ES identified additional medically actionable variant calls and helped resolve ambiguous single nucleotide variants (SNV) documenting the power of increased depth of coverage of the captured targeted regions. Comparative analyses of WGS and ES reveal that pseudogenes and segmental duplications may explain some instances of apparent disease mutations in unaffected individuals.
- 27 June 2013
- Published by Springer Nature in Genome Medicine
- Vol. 5 (6) , 57
Open AccessExome sequencing resolves apparent incidental findings and reveals further complexity of SH3TC2 variant alleles causing Charcot-Marie-Tooth neuropathy
Background: The debate regarding the relative merits of whole genome sequencing (WGS) versus exome sequencing (ES) centers around comparative cost, average depth of coverage for each interrogated base, and their relative efficiency in the identification of medically actionable variants from the myriad of variants identified by each approach. Nevertheless, few genomes have been subjected to both WGS and ES, using multiple next generation sequencing platforms. In addition, no personal genome has been so extensively analyzed using DNA derived from peripheral blood as opposed to DNA from transformed cell lines that may either accumulate mutations during propagation or clonally expand mosaic variants during cell transformation and propagation. Methods: We investigated a genome that was studied previously by SOLiD chemistry using both ES and WGS, and now perform six independent ES assays (Illumina GAII (x2), Illumina HiSeq (x2), Life Technologies' Personal Genome Machine (PGM) and Proton), and one additional WGS (Illumina HiSeq). Results: We compared the variants identified by the different methods and provide insights into the differences among variants identified between ES runs in the same technology platform and among different sequencing technologies. We resolved the true genotypes of medically actionable variants identified in the proband through orthogonal experimental approaches. Furthermore, ES identified an additional SH3TC2 variant (p.M1?) that likely contributes to the phenotype in the proband. Conclusions: ES identified additional medically actionable variant calls and helped resolve ambiguous single nucleotide variants (SNV) documenting the power of increased depth of coverage of the captured targeted regions. Comparative analyses of WGS and ES reveal that pseudogenes and segmental duplications may explain some instances of apparent disease mutations in unaffected individuals.
- 1 April 2013
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 68 (4) , 276-278
Chromosomal Microarray Versus Karyotyping for Prenatal Diagnosis
Array-based molecular cytogenetic techniques have improved the detection of small genomic deletions and duplications not seen on karyotyping. These copy-number variants can be benign or pathogenic, depending on their location and genetic content. Whether microarray analysis reliably detects all chromosome abnormalities diagnosed on standard karyotyping and how often abnormal microarray results are not detected on karyotyping are unknown. This large, prospective study was performed at 29 prenatal centers to assess the capability of microarray analysis to diagnose common chromosome abnormalities and to determine the amount of additional data possible using microarray compared with standard karyotyping. Women presenting with a singleton fetus for chorionic villus sampling or amniocentesis for indications including advanced maternal age, a positive aneuploidy screening result, and ultrasound-detected anomalies were eligible. Each sample was split into 2 portions, one for karyotyping and the other for microarray analysis. Each microarray result was considered as true positive, true negative, false positive, or false negative relative to the karyotype findings. Karyotyping was considered the standard against which the chromosomal microarray was judged for identifying common autosomal and sex-chromosome aneuploidies. Karyotyping and microarray assays were performed according to standard protocols. Variants determined not to be of clinical importance were classified as “likely benign” and were not reported to the participant. The rest were determined to be of potential clinical significance and were reported to the participant. Adequate samples were obtained from 4406 of 6537 women screened. Samples for microarray were available from 4391 women (99.7%), and analysis was successful in 4340 cases (98.8%). The primary analysis included 4282 samples, in which 317 (7.4%) common autosomal and 57 (1.3%) sex-chromosome aneuploidies were identified by standard karyotyping. Microarray analysis identified all of these aneuploidies. All 22 unbalanced rearrangements also were identified by microarray. None of the apparently balanced rearrangements identified on karyotyping were identified by microarray analysis, suggesting that these rearrangements were truly balanced. Seventeen triploid samples (0.4%) were present, none of which were identified on microarray. On microarray, 1399 samples had copy-number variants, of which 1234 (88.2%) were classified as common benign. Thirty-five copy-number variants (0.9%) among the 3822 fetuses were on a predetermined list of pathogenic copy-number variants. Of 130 samples, 36 (27.7%) were likely benign, and 94 were considered of uncertain significance. Sixty-one (64.9%) of these 94 had sufficient clinical relevance to be reported to the participant. Overall, 96 (2.5%) of the 3822 fetal samples with normal karyotypes had a microdeletion or duplication of clinical significance. From fetuses with suspected growth or structural anomalies, 45 (6.0%) of the 755 samples had clinically relevant findings on microarray that were not found on karyotyping. Thirty-four (1.7%) of 1966 women without ultrasound-identified anomalies tested because of older age had a normal karyotype and a clinically relevant finding on microarray as did 12 (1.6%) of 729 women who tested positive on Down syndrome screening. Microarray analysis is equivalent to standard karyotype analysis for prenatal diagnosis of common aneuploidies and can be beneficial for prenatal testing. Patients should be aware of the risks of invasive testing, the frequency and severity of clinically relevant microarray findings, and the more limited identification of common aneuploidies obtainable by noninvasive screening. Still under study are how much incremental information should be sought by prenatal testing and how that information should be introduced into care.
- 1 April 2013
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 68 (4) , 276-278
Chromosomal Microarray Versus Karyotyping for Prenatal Diagnosis
Array-based molecular cytogenetic techniques have improved the detection of small genomic deletions and duplications not seen on karyotyping. These copy-number variants can be benign or pathogenic, depending on their location and genetic content. Whether microarray analysis reliably detects all chromosome abnormalities diagnosed on standard karyotyping and how often abnormal microarray results are not detected on karyotyping are unknown. This large, prospective study was performed at 29 prenatal centers to assess the capability of microarray analysis to diagnose common chromosome abnormalities and to determine the amount of additional data possible using microarray compared with standard karyotyping. Women presenting with a singleton fetus for chorionic villus sampling or amniocentesis for indications including advanced maternal age, a positive aneuploidy screening result, and ultrasound-detected anomalies were eligible. Each sample was split into 2 portions, one for karyotyping and the other for microarray analysis. Each microarray result was considered as true positive, true negative, false positive, or false negative relative to the karyotype findings. Karyotyping was considered the standard against which the chromosomal microarray was judged for identifying common autosomal and sex-chromosome aneuploidies. Karyotyping and microarray assays were performed according to standard protocols. Variants determined not to be of clinical importance were classified as “likely benign” and were not reported to the participant. The rest were determined to be of potential clinical significance and were reported to the participant. Adequate samples were obtained from 4406 of 6537 women screened. Samples for microarray were available from 4391 women (99.7%), and analysis was successful in 4340 cases (98.8%). The primary analysis included 4282 samples, in which 317 (7.4%) common autosomal and 57 (1.3%) sex-chromosome aneuploidies were identified by standard karyotyping. Microarray analysis identified all of these aneuploidies. All 22 unbalanced rearrangements also were identified by microarray. None of the apparently balanced rearrangements identified on karyotyping were identified by microarray analysis, suggesting that these rearrangements were truly balanced. Seventeen triploid samples (0.4%) were present, none of which were identified on microarray. On microarray, 1399 samples had copy-number variants, of which 1234 (88.2%) were classified as common benign. Thirty-five copy-number variants (0.9%) among the 3822 fetuses were on a predetermined list of pathogenic copy-number variants. Of 130 samples, 36 (27.7%) were likely benign, and 94 were considered of uncertain significance. Sixty-one (64.9%) of these 94 had sufficient clinical relevance to be reported to the participant. Overall, 96 (2.5%) of the 3822 fetal samples with normal karyotypes had a microdeletion or duplication of clinical significance. From fetuses with suspected growth or structural anomalies, 45 (6.0%) of the 755 samples had clinically relevant findings on microarray that were not found on karyotyping. Thirty-four (1.7%) of 1966 women without ultrasound-identified anomalies tested because of older age had a normal karyotype and a clinically relevant finding on microarray as did 12 (1.6%) of 729 women who tested positive on Down syndrome screening. Microarray analysis is equivalent to standard karyotype analysis for prenatal diagnosis of common aneuploidies and can be beneficial for prenatal testing. Patients should be aware of the risks of invasive testing, the frequency and severity of clinically relevant microarray findings, and the more limited identification of common aneuploidies obtainable by noninvasive screening. Still under study are how much incremental information should be sought by prenatal testing and how that information should be introduced into care.
- Open Access
- 6 July 2011
- Published by Springer Nature in International Journal of Pediatric Endocrinology
- Vol. 2011 (1) , 5
Early onset obesity and adrenal insufficiency associated with a homozygous POMC mutation
Isolated hypocortisolism due to ACTH deficiency is a rare condition that can be caused by homozygous or compound heterozygous mutations in the gene encoding proopiomelanocortin (POMC). Loss of function mutations of POMC gene typically results in adrenal insufficiency, obesity and red hair. We describe an 18 month old Hispanic female with congenital adrenal insufficiency, a novel POMC mutation and atypical clinical features. The patient presented at the age of 9 months with hypoglycemia and the endocrine evaluation resulted in a diagnosis of ACTH deficiency. She developed extreme weight gain prompting sequence analysis of POMC, which revealed a homozygous c.231C > A change which is predicted to result in a premature termination codon. The case we report had obesity, hypocortisolism but lacked red hair which is typical for subjects with POMC mutations. Mutations of POMC should be considered in individuals with severe early onset obesity and adrenal insufficiency even when they lack the typical pigmentary phenotype.
- 6 July 2011
- Published by Springer Nature in International Journal of Pediatric Endocrinology
- Vol. 2011 (1) , 5
Open AccessEarly onset obesity and adrenal insufficiency associated with a homozygous POMC mutation
Isolated hypocortisolism due to ACTH deficiency is a rare condition that can be caused by homozygous or compound heterozygous mutations in the gene encoding proopiomelanocortin (POMC). Loss of function mutations of POMC gene typically results in adrenal insufficiency, obesity and red hair. We describe an 18 month old Hispanic female with congenital adrenal insufficiency, a novel POMC mutation and atypical clinical features. The patient presented at the age of 9 months with hypoglycemia and the endocrine evaluation resulted in a diagnosis of ACTH deficiency. She developed extreme weight gain prompting sequence analysis of POMC, which revealed a homozygous c.231C > A change which is predicted to result in a premature termination codon. The case we report had obesity, hypocortisolism but lacked red hair which is typical for subjects with POMC mutations. Mutations of POMC should be considered in individuals with severe early onset obesity and adrenal insufficiency even when they lack the typical pigmentary phenotype.